- Free from Publisher B Ahrén, R Gomis, E Standl, D Mills, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1%
and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change
from a baseline of 7.9 ± 0.1% in patients given placebo (between-group ... Cited by 310 - Related articles - BL Direct - All 8 versions
- ►endojournals.org B Ahren, M Landin-Olsson, PA Jansson, M … - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc The stimulation of insulin vs. inhibition of glucagon secretion in relation to
the antidiabetic action of glucagon-like peptide-1 (GLP-1) is not established.
Here, the influence of a 4-wk increase in circulating GLP-1 by inhibition ... Cited by 329 - Related articles - BL Direct - All 7 versions
- ►endojournals.org A Mari, WM Sallas, YL He, C Watson, M … - Journal of Clinical Endocrinology & Metabolism, 2005 - Endocrine Soc Results: Vildagliptin significantly increased the insulin secretory rate at 7
mmol/liter glucose (secretory tone), calculated from the dose response; the
difference in least squares mean ( LSM) was 101 ± 51 pmol·min –1 ·m ... Cited by 193 - Related articles - BL Direct - All 8 versions
- Free from Publisher B Ahrén, G Pacini, JE Foley, A Schweizer - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—In subjects completing 52 weeks with participation in all meal tests
(n = 57), HbA 1c (A1C) decreased in the vildagliptin/metformin group (VM group,
n = 31) but increased in the placebo/metformin group (PM group, n = 26; ... Cited by 176 - Related articles - BL Direct - All 9 versions
S Ristic, S Byiers, J Foley, D Holmes - Diabetes Obesity and Metabolism, 2005 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 138 - Related articles - BL Direct - All 4 versions
D Holmes - Horm Metab Res, 2006 - rima.org The incretin hormones ± glucose−dependent insulinotropic poly− peptide
(GIP) and particularly glucagon−like peptide−1 (GLP−1) ± have been
reported to exert multiple metabolic effects that con− tribute to the ... Cited by 119 - Related articles - View as HTML - BL Direct - All 4 versions
- ►diabetesjournals.org E Bosi, RP Camisasca, C Collober, E … - Diabetes Care, 2007 - Am Diabetes Assoc RESULTS—The between-treatment difference (vildagliptin − placebo) in
adjusted mean change (AMΔ) ± SE in A1C from baseline to end point was −0.7
± 0.1% (P < 0.001) and −1.1 ± 0.1% (P < 0.001) in patients receiving 50 ... Cited by 147 - Related articles - BL Direct - All 10 versions
- Free from Publisher J Rosenstock, MA Baron, S Dejager, D Mills, … - Diabetes Care, 2007 - ncbi.nlm.nih.gov OBJECTIVE: To compare the efficacy and tolerability of vildagliptin and
rosiglitazone during a 24-week treatment in drug-naïve patients with type 2
diabetes. RESEARCH DESIGN AND METHODS: This was a double-blind, randomized, ... Cited by 142 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 454 - Related articles - BL Direct - All 13 versions
- ►januvia.se [PDF] - Free from Publisher B Charbonnel, A Karasik, J Liu, M Wu, G … - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—After a screening diet/exercise run-in period, a
metformin dose titration/stabilization period, and a 2-week, single-blind,
placebo run-in period, 701 patients, aged 19–78 years, with mild to ... Cited by 202 - Related articles - BL Direct - All 9 versions
